| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/13/2009 | US20090203683 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| 08/13/2009 | US20090203673 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments |
| 08/13/2009 | US20090203666 Compounds and compositions as hedgehog pathway modulators |
| 08/13/2009 | US20090203663 Chemical compounds |
| 08/13/2009 | US20090203648 Modified phosphocalcic compound, injectable composition containing same |
| 08/13/2009 | US20090203640 Crystalline forms of gemcitabine amide prodrug, compositions and use thereof |
| 08/13/2009 | US20090203637 Novel cytostatic 7-deazapurine nucleosides |
| 08/13/2009 | US20090203636 Prevention and Treatment of Cancer and Other Diseases |
| 08/13/2009 | US20090203634 Compositions and Uses of Amooranin Compounds |
| 08/13/2009 | US20090203624 Alpha-fetoprotein peptides |
| 08/13/2009 | US20090203623 METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST |
| 08/13/2009 | US20090203622 Method of treating metastatic stage prostate cancer |
| 08/13/2009 | US20090203615 Use of activity dependent neurotrophic factor for enhancing learning and memory: pre-and post-natal administration |
| 08/13/2009 | US20090203601 Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (G-CSF) variant |
| 08/13/2009 | US20090203594 Anticancer peptide |
| 08/13/2009 | US20090203590 Method for the inhibition of angiogenesis |
| 08/13/2009 | US20090203589 Chemically modified human growth hormone receptor antagonist conjugates |
| 08/13/2009 | US20090203588 Outcome prediction and risk classification in childhood leukemia |
| 08/13/2009 | US20090203587 Diagnosis and Therapy of Cell Proliferative Disorders Characterized by Resistance to Trail Induced Apoptosis |
| 08/13/2009 | US20090203584 Peptide-based Compounds |
| 08/13/2009 | US20090203124 Mage-a3 peptides presented by hla-dr1 molecules |
| 08/13/2009 | US20090203121 Nucleic acid agents for downregulating h19, and methods of using same |
| 08/13/2009 | US20090203114 Novel methods and interferon deficient substrates for the propagation of viruses |
| 08/13/2009 | US20090203072 Detection for HPV-Induced invasive cancers and their precursor lesions with invasive potential |
| 08/13/2009 | US20090203044 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 08/13/2009 | US20090203036 Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
| 08/13/2009 | US20090203024 Secreted protein called 36p6d5 characteristic of tumors |
| 08/13/2009 | US20090202650 Methods of treating cancers |
| 08/13/2009 | US20090202638 Bmp gene and fusion protein |
| 08/13/2009 | US20090202623 Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent |
| 08/13/2009 | US20090202595 Anti-pdef antibodies and uses thereof |
| 08/13/2009 | US20090202592 Cytolethal distending toxin, inhibition and use thereof |
| 08/13/2009 | US20090202587 Compositions comprising hmw-maa and fragments thereof, and methods of use thereof |
| 08/13/2009 | US20090202577 CASB618 Polynucleotides and Polypeptides and Their Use |
| 08/13/2009 | US20090202575 Immunostimulatory nucleic acid molecules |
| 08/13/2009 | US20090202574 Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer |
| 08/13/2009 | US20090202571 Bioreductively-activated prodrugs |
| 08/13/2009 | US20090202570 Pm-2 antibodies, functional fragments and methods for treating metastasis |
| 08/13/2009 | US20090202567 Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm |
| 08/13/2009 | US20090202566 Use of the ENDO-180 gene and polypeptide for diagnosis and treatment |
| 08/13/2009 | US20090202561 Novel raag10 cell surface target and a family of antibodies recognizing that target |
| 08/13/2009 | US20090202560 Method for diagnosing efficacy of xenotypic antibody therapy |
| 08/13/2009 | US20090202556 Anti-claudin-4 antibody |
| 08/13/2009 | US20090202552 Gene expressed in prostate cancer and methods of use |
| 08/13/2009 | US20090202550 Monoclonal antibodies and immunodetection assay specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor |
| 08/13/2009 | US20090202547 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 08/13/2009 | US20090202545 Melanoma biomarker and methods of uses |
| 08/13/2009 | US20090202541 Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| 08/13/2009 | US20090202540 Substituted oxazaphosphorines |
| 08/13/2009 | US20090202539 METHOD FOR TREATING CANCER USING ANTI-WNT2 MONOCLONAL ANTIBODIES AND siRNA |
| 08/13/2009 | US20090202537 FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
| 08/13/2009 | US20090202536 Antibody-drug conjugates and methods |
| 08/13/2009 | US20090202534 Compositions and methods for modulating immune responses |
| 08/13/2009 | US20090202513 Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer |
| 08/13/2009 | US20090202508 Negative regulation of hypoxia inducible factor 1 by os-9 |
| 08/13/2009 | US20090202507 Intelligent Nanomedicine Integrating Diagnosis And Therapy |
| 08/13/2009 | US20090202504 Methods for the detection and prognosis of breast tumors |
| 08/13/2009 | US20090202503 Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof |
| 08/13/2009 | US20090202489 Adenoviruses mutated in the va genes for cancer treatment |
| 08/13/2009 | US20090202487 Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology |
| 08/13/2009 | US20090202473 Combination of an anti-edb fibronectin antibody-il-2 fusion protein, and a molecule binding to b cells, b cell progenitors and/or their cancerous counterpart |
| 08/13/2009 | US20090202443 Methods of improving skin quality |
| 08/13/2009 | US20090202441 Compositions and methods to prevent cancer with cupredoxins |
| 08/13/2009 | US20090202440 Model animal of dendritic cell immunoreceptor gene knockout disease |
| 08/13/2009 | US20090202439 Methods for treatment of angiogenesis |
| 08/13/2009 | US20090202438 Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
| 08/13/2009 | DE202009006461U1 Kombination von Tocotrienolen mit ungesättigten Fettsäuren als Mittel zum Schutz des Herz/Kreislaufsystems, vor Krebserkrankungen, zur Entzündungshemmung, zur Steigerung der geistigen Leistungsfähigkeit und gegen Altersbeschwerden Combination of tocotrienols with unsaturated fatty acids as a means to protect the heart / circulatory system against cancer, reduces inflammation, increase mental performance and complaints against age |
| 08/13/2009 | DE102008007440A1 Aminosäurederivate als Arzneistoffe Amino acid derivatives as drugs |
| 08/13/2009 | DE102008007381A1 Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten Amidines and guanidines and their derivatives for the treatment of diseases |
| 08/13/2009 | CA2724230A1 Platinum aggregates and process for producing the same |
| 08/13/2009 | CA2715329A1 Picoplatin and amrubicin to treat lung cancer |
| 08/13/2009 | CA2714547A1 Ruthenium compounds and compositions |
| 08/13/2009 | CA2714181A1 Ampk modulators |
| 08/13/2009 | CA2714071A1 Alpha 5 - beta 1 antibodies and their uses |
| 08/13/2009 | CA2713933A1 Camptothecin-binding moiety conjugates |
| 08/13/2009 | CA2713504A1 Anti-cd79b antibodies and immunoconjugates and methods of use |
| 08/13/2009 | CA2713438A1 Treatment of bladder diseases with a tlr7 activator |
| 08/13/2009 | CA2713032A1 Treatment of diseases and conditions mediated by eicosanoids |
| 08/13/2009 | CA2712518A1 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 08/13/2009 | CA2712080A1 Breaking immunological tolerance with a genetically encoded unnatural amino acid |
| 08/13/2009 | CA2711798A1 Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
| 08/13/2009 | CA2711778A1 Pyrrolopyrimidine derivative as pi3k inhibitor and use thereof |
| 08/13/2009 | CA2711777A1 Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer drugs |
| 08/13/2009 | CA2711399A1 3-substituted sulfonylpiperidine derivative |
| 08/13/2009 | CA2711078A1 Furo- and thieno[3,2-c] pyridines |
| 08/13/2009 | CA2706812A1 Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof |
| 08/12/2009 | EP2088193A1 Novel shuttle vector |
| 08/12/2009 | EP2088159A1 Antibody recognizing c-domain of midkine |
| 08/12/2009 | EP2088150A1 Fused pyrrolocarbazoles and methods for the preparation thereof |
| 08/12/2009 | EP2088141A2 Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same |
| 08/12/2009 | EP2087912A1 ENVIRONMENT-RESPONDING siRNA CARRIER USING DISULFIDE-BRIDGED POLYMERIC MICELLE |
| 08/12/2009 | EP2087907A2 Method and system to remove cytokine inhibitor in patients |
| 08/12/2009 | EP2087904A1 Therapeutic use of peptides derived from Bcl-XL protein in cancer patients |
| 08/12/2009 | EP2087891A2 Pharmaceutical compositions for treating lymphoma |
| 08/12/2009 | EP2087115A2 Blocking of gene expression in eukaryotic cells |
| 08/12/2009 | EP2087103A1 Cancerous disease modifying antibodies |
| 08/12/2009 | EP2087093A1 Incorporation of active molecules into microalga |
| 08/12/2009 | EP2087005A2 Compounds |
| 08/12/2009 | EP2086999A1 Inhibitors for disrupting the interaction of ubiquitination related enzymes and uses thereof |
| 08/12/2009 | EP2086981A1 Compounds for inhibiting mitotic progression |